title: Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.
abstract: It is now well established that metastatic colorectal cancer patients without KRAS mutation (codon 12) benefit from treatment with an epidermal growth factor receptor monoclonal antibody (anti-EGFR mAb). Recently, EFGR and KRAS mutations have been shown to exist in patients who developed resistance to anti-EGFR mAb. We analyzed KRAS, BRAF V600E and EGFR S492R mutations in 37 post-anti-EGFR mAb tumor samples from 23 patients treated with chemotherapy plus anti-EGFR mAb. No EGFR S492R mutation was detected. A KRAS mutation was found after anti-EGFR mAb in only one tumor. Our results suggest that acquired EGFR S492R and KRAS mutations do not constitute the main mechanism of resistance to anti-EGFR mAb in combination with chemotherapy.
authors.affiliation: Department of Gastroenterology, Poitiers University Hospital, 2 rue de la Milétrie, Poitiers Cedex, France. davidtougeron@hotmail.fr
authors.forename: David
authors.initials: D
authors.lastname: Tougeron
authors.forename: Ulrich
authors.initials: U
authors.lastname: Cortes
authors.forename: Aurélie
authors.initials: A
authors.lastname: Ferru
authors.forename: Claire
authors.initials: C
authors.lastname: Villalva
authors.forename: Christine
authors.initials: C
authors.lastname: Silvain
authors.forename: Jean Marc
authors.initials: JM
authors.lastname: Tourani
authors.forename: Pierre
authors.initials: P
authors.lastname: Levillain
authors.forename: Lucie
authors.initials: L
authors.lastname: Karayan-Tapon
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D003131:Combined Modality Therapy; D018450:Disease Progression; D066246:ErbB Receptors / Q000235:genetics* / Q000276:immunology*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics* / Q000502:physiology*; D009362:Neoplasm Metastasis; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras); D016896:Treatment Outcome; D018631:ras Proteins / Q000235:genetics*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; D066246:ErbB Receptors; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins